- Home
- TECX vs FFA Comparison
TECX vs FFA Comparison
Compare TECX & FFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- FFA
- Stock Information
- Founded
- TECX 2019
- FFA 2004
- Country
- TECX United States
- FFA United States
- Employees
- TECX N/A
- FFA N/A
- Industry
- TECX
- FFA Investment Managers
- Sector
- TECX
- FFA Finance
- Exchange
- TECX Nasdaq
- FFA Nasdaq
- Market Cap
- TECX 334.4M
- FFA 400.0M
- IPO Year
- TECX 2018
- FFA N/A
- Fundamental
- Price
- TECX $21.51
- FFA $19.73
- Analyst Decision
- TECX Buy
- FFA
- Analyst Count
- TECX 6
- FFA 0
- Target Price
- TECX $79.20
- FFA N/A
- AVG Volume (30 Days)
- TECX 172.8K
- FFA 26.1K
- Earning Date
- TECX 05-08-2025
- FFA 01-01-0001
- Dividend Yield
- TECX N/A
- FFA 6.72%
- EPS Growth
- TECX N/A
- FFA N/A
- EPS
- TECX N/A
- FFA N/A
- Revenue
- TECX N/A
- FFA N/A
- Revenue This Year
- TECX N/A
- FFA N/A
- Revenue Next Year
- TECX N/A
- FFA N/A
- P/E Ratio
- TECX N/A
- FFA N/A
- Revenue Growth
- TECX N/A
- FFA N/A
- 52 Week Low
- TECX $13.70
- FFA $15.84
- 52 Week High
- TECX $61.07
- FFA $19.30
- Technical
- Relative Strength Index (RSI)
- TECX 51.42
- FFA 62.28
- Support Level
- TECX $21.20
- FFA $19.21
- Resistance Level
- TECX $22.75
- FFA $19.78
- Average True Range (ATR)
- TECX 1.43
- FFA 0.18
- MACD
- TECX 0.01
- FFA -0.00
- Stochastic Oscillator
- TECX 41.32
- FFA 91.23
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.